

Remarks/Arguments:

Status of the Application

In the Office Action, claims 1-10, 13, 14, and 17-21 were allowed and claim 16 rejected. In the present Response, claim 16 has been cancelled without prejudice to the subject matter claimed therein and claims 1-6, 8, and 19-21 have been amended to correct obvious typographical errors so that claims 1-10, 13, 14, and 17-21 are pending.

Applicants representative spoke to Examiner Moore regarding incorrectly noted information on PTO form PTOL-303. Specifically, form PTOL-303 states Applicants response to the Final Office Action mailed October 2, 2006 was filed December 27, 2006, when in fact Applicants filed the response December 4, 2006. Moreover, PTO form PTOL-303 fails to recognize that Applicants responded to the Final Office Action mailed October 2, 2006 within two-months of the mailing of the Final Office Action. It is of import to note that the 2-month date fell on Saturday, December 2, 2006 and Applicants filed the response to the Final Office action at issue on the next business day of Monday, December 4, 2006. Accordingly, Applicants respectfully solicit a corrected PTO form PTOL-303 indicating extensions of time for filing additional responses to the Final Office Action are to be calculated from the mailing date of the Advisory Action. As the response to the Final Office Action was mailed within 2-months from the date of the mailing of the final Office Action AND the current response is being mailed within 1-month from the date of the mailing of the Advisory Action, Applicants are only responsible for securing a 1-month extension of time.

Claims 1-6, 8, and 19-21 have been amended to correct obvious typographical errors and not for reasons related to patentability. Specifically, claims 1-6, 8, and 19-21 have been amended to: a) delete the term "halogen," which due to a typographical error was set forth twice in the list of named substituents; b) delete the term "wherein", which due to a typographical error was stated twice; and/or c) replace " C_{3-6} cycloalkyl-C₁₋₄alkyl" with " C_{3-10} cycloalkyl-C₁₋₄alkyl", which due to a typographical error was misstated (support for this amendment can be found at page 8, lines 6-7 and page 20, line 15).

Applicants have also amended the specification throughout to correct the same typographical errors noted in claims 1-6, 8, and 19-21. No new matter has been added.

SUMMARY

In view of the cancellation of claim 16, Applicants respectfully submit that previously allowed claims 1-10, 13, 14, and 17-21 are in condition for allowance. Accordingly, Applicants

respectfully solicit a Notice of Allowance. In order to expedite disposition of this case, the Office is invited to contact Applicants' representative at the telephone number below to resolve any remaining issues.

Although Applicants believe no additional fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment(s) to deposit account No. 26-0166, referencing Attorney Docket No. 100884-1 US.

AstraZeneca Pharmaceuticals
Global Intellectual Property, Patents,
1800 Concord Pike
Wilmington, DE-19850-5437
302-885-4269
Dated: 2/5/2006

Respectfully submitted,

/Jacqueline Cohen/
Jacqueline M. Cohen
Attorney for Applicants
Reg. No.: 51,574